The role of bDMARDs in the prevention and treatment of inflammatory-related comorbidities in Psoriatic Arthritis

被引：2

作者：

Caso, Francesco ^{[1
]}

Fatica, Mauro ^{[2
]}

Ferraioli, Mario ^{[2
]}

Megna, Matteo ^{[3
]}

Potestio, Luca ^{[3
]}

Ruggiero, Angelo ^{[3
]}

Tommasino, Nello ^{[3
]}

Maione, Francesco ^{[4
]}

Scarpa, Raffaele ^{[1
]}

Chimenti, Maria Sole ^{[2
]}

Costa, Luisa ^{[1
]}

机构：

[1] Univ Naples Federico II, Dept Clin Med & Surg, Via S Pansini 5, I-80131 Naples, Italy

[2] Univ Roma Tor Vergata, Dipartimento Med Sistemi, UOC Reumatol, Rome, Italy

[3] Univ Naples Federico II, Dept Clin Med & Surg, Sect Dermatol, Naples, Italy

[4] Univ Naples Federico II, Sch Med & Surg, Dept Pharm, ImmunoPharmaLab, Naples, Italy

来源：

EXPERT OPINION ON BIOLOGICAL THERAPY | 2024年 / 24卷 / 08期

关键词：

Psoriatic arthritis; bDMARDs; comorbidities; obesity; metabolic syndrome; depression; osteoporosis; NASH; NECROSIS-FACTOR-ALPHA; CARDIOVASCULAR RISK-FACTORS; DISEASE-ACTIVITY; RHEUMATOID-ARTHRITIS; METABOLIC SYNDROME; MANAGEMENT; EVENTS; DIAGNOSIS; IMPACT; DYSLIPIDEMIA;

D O I：

10.1080/14712598.2024.2384090

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

IntroductionPsoriatic arthritis (PsA) is an immune-inflammatory disease that affects both joints and entheses, and with diverse extra-articular manifestations (psoriasis, inflammatory bowel disease (IBD), and uveitis). A wide range of comorbid conditions, including cardiovascular diseases, obesity, metabolic syndrome (MetS), nonalcoholic fatty liver disease (NAFLD), mental health disorders (depression/anxiety), and osteoporosis are highly prevalent in course of PsA.Biological DMARDs (bDMARD), including TNF-inhibitors (TNFi), Interleukin (IL-17i) and IL-23i represent the cornerstone of the management of active disease. The use of these therapies obviously requires considering comorbidities presence, safety aspects and contraindications.IntroductionPsoriatic arthritis (PsA) is an immune-inflammatory disease that affects both joints and entheses, and with diverse extra-articular manifestations (psoriasis, inflammatory bowel disease (IBD), and uveitis). A wide range of comorbid conditions, including cardiovascular diseases, obesity, metabolic syndrome (MetS), nonalcoholic fatty liver disease (NAFLD), mental health disorders (depression/anxiety), and osteoporosis are highly prevalent in course of PsA.Biological DMARDs (bDMARD), including TNF-inhibitors (TNFi), Interleukin (IL-17i) and IL-23i represent the cornerstone of the management of active disease. The use of these therapies obviously requires considering comorbidities presence, safety aspects and contraindications.Areas coveredThe aim of this review is to describe the inflammatory mechanisms behind PsA comorbidities, and the role of bDMARDs in the prevention and treatment of these conditions in course of PsA.Expert opinionTailoring therapeutic strategies to the individual characteristics of each PsA patient can be an effective approach to manage comorbidities, maximizing the efficacy of bDMARDs, and reducing the incidence of AEs. Identifying targets within disease pathways can guide research into therapeutics that address both PsA and comorbidities simultaneously, but more studies are advocated for clarifying the potential prevention and management of bDMARDs used for PsA.

引用

页码：719 / 731

页数：13

共 140 条

[1] Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases [J].